Outcomes of treatment with sorafenib in Egyptian patients with hepatocellular carcinoma: a retrospective cohort study

Nada, Yousery; Rashad, Noha; Eissa, Mai; Ghonaim, Aya; Farag, Kyrillus; Saadawi, Islam; Sheha, Ahmed M.; Gewaity, Mahmoud El; Abdel‐Rahman, Omar

doi:10.1080/17474124.2018.1403898

Cited by 7 publications

(6 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Egypt, in a previous retrospective study, the most frequent grade 3/4 adverse events reported were HFS, fatigue, and diarrhea in 27.6% of the patients [26]. In the single-arm study, 23% of the patients suffered from fatigue, diarrhea, and HFS (grade 3/4 toxicity) [25].…”

Section: Side Effectsmentioning

confidence: 95%

“…In the Sorafenib group, the median OS was not reached as more than 50% were still alive at the end of the study. While the two previously mentioned Egyptian studies presented that median OS for patients treated with sorafenib was 6 & 5 months only [25,26]. Additionally, all the previous studies were uncontrolled, which leads to limitations.…”

Section: Previous Egyptian Population Studiesmentioning

confidence: 97%

See 1 more Smart Citation

Efficacy and Safety of Sorafenib Versus Supportive Care in Egyptian Advanced Hepatocellular Carcinoma Patients

Baghdady¹,

Elwakeel

Ellithy

et al. 2020

Archives of Pharmaceutical Sciences Ain Shams University

View full text Add to dashboard Cite

Section: Side Effectsmentioning

confidence: 95%

Section: Previous Egyptian Population Studiesmentioning

confidence: 97%

Efficacy and Safety of Sorafenib Versus Supportive Care in Egyptian Advanced Hepatocellular Carcinoma Patients

Baghdady¹,

Elwakeel

Ellithy

et al. 2020

Archives of Pharmaceutical Sciences Ain Shams University

View full text Add to dashboard Cite

“…A study on sorafenib in Egypt claimed that it cannot be used except in patients with Child A and low disease burden[ 170 ]. The same recommendation was made by Abdel-Rahman et al [ 171 ].…”

Section: Treatment Of Hcc In Egyptmentioning

confidence: 99%

Unique situation of hepatocellular carcinoma in Egypt: A review of epidemiology and control measures

Ezzat¹,

Eltabbakh²,

Kassas³

2021

WJGO

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the sixth most common primary malignancy worldwide, and the third most common cause of death among cancers worldwide. HCC occurs in several pre-existing conditions, including hepatitis C, hepatitis B virus, and non-alcoholic cirrhosis. Egypt used to be the country with the heaviest hepatitis C virus (HCV) burden. The relationship between HCV and HCC is an important research area. In Egypt, HCC is a significant public health problem. A possible cause for the increasing rates of detection of HCC in Egypt is the mass screening program that was carried by the government for detecting and treating HCV. A multidisciplinary approach is now widely applied to HCC management in health centers all over Egypt. Different treatment modalities are available in Egypt, with success rates comparable to global rates. The Egyptian health authorities have made the elimination of HCV from Egypt a special priority, and this approach should lead to a decrease in number of HCC cases in the near future. In this article we review the current situation of HCC in Egypt, including epidemiological aspects, relevant risk factors for HCC development, strategies, and efforts established by health authorities for the screening and prevention of both HCV and HCC in Egypt. We highlight the different modalities for HCC treatment.

show abstract

“…The disease control rate was 45.4% with 2 patients experiencing complete remission (1.2%). 145 Immune checkpoint inhibitors have the potential to substantially alter first line treatment for HCC. 146 Unfortunately, it was recently reported that a study of pembrolizumab versus sorafenib in first line treatment of HCC did not meet the target endpoint and was negative.…”

Section: Future Trendsmentioning

confidence: 99%

Epidemiology of Liver Cancer in Africa: Current and Future Trends

et al. 2019

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a disease of global public health significance with mortality on the rise, despite the preventable nature of its risk factors especially in Africa. It is now the sixth most common cancer worldwide, fifth in males, and ninth in females. HCC incidence and mortality are predicted to increase in African countries constrained by limited resources to combat endemic levels of viral infection and synergistic environmental risk factors. The changing nature of HCC etiology is particularly illustrated here with the traditional risk factors like viral hepatitis coexisting alongside high human immunodeficiency virus (HIV) prevalence and rapidly increasing urbanization that have promoted a sharp increase in additional risk factors like coinfection, type 2 diabetes mellitus, and obesity. Although there are some differences in etiology between North Africa and sub-Saharan Africa, risk factors like chronic viral hepatitis B and C, aflatoxin exposure, and iron overload predominate. Aggressive hepatitis B genotypes, combined with hepatitis B virus/hepatitis C virus/HIV coinfections and aflatoxin exposure, promote a more aggressive molecular phenotype. In parallel to a better understanding of the molecular etiology of HCC, policy and planning initiatives to address the burden of HCC must be anchored within the reality of the limited resources available. Establishment and coordination of cancer registries across Africa is needed to improve the quality of data necessary to galvanize action. Preventive measures including hepatitis B vaccination programs, measures to prevent maternal-to-child and child-to-child transmission, delivery of universally accessible antiretroviral and antiviral treatments, and reduction of dietary aflatoxin exposure can contribute markedly to reduce HCC incidence. Finally, the development of biomarkers and new therapeutic interventions will need a better understanding of the unique genetic and epigenetic characteristics of HCC on the continent. We present a narrative review of HCC in Africa, discussing present and future trends.

show abstract

Outcomes of treatment with sorafenib in Egyptian patients with hepatocellular carcinoma: a retrospective cohort study

Abstract: Sorafenib use should be limited to patients with Child A, PS 0-1, and low disease burden.

Cited by 7 publications

References 38 publications

Efficacy and Safety of Sorafenib Versus Supportive Care in Egyptian Advanced Hepatocellular Carcinoma Patients

Efficacy and Safety of Sorafenib Versus Supportive Care in Egyptian Advanced Hepatocellular Carcinoma Patients

Unique situation of hepatocellular carcinoma in Egypt: A review of epidemiology and control measures

Epidemiology of Liver Cancer in Africa: Current and Future Trends

Contact Info

Product

Resources

About